SCYX
SCYNEXIS INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$4.46
+0.22%Sep 10, 2026, 12:12 UTC
SCYNEXIS Inc. appointed Sanjay Subramanian as Chief Financial Officer effective September 9, 2026.
Source:Sep 10, 2026, 12:12 UTC
SCYNEXIS Inc. Chief Financial Officer Ivor Macleod retired effective September 9, 2026.
Aug 25, 2026, 23:06 UTC
SCYNEXIS, Inc. granted an inducement equity award to a new Senior Director in connection with the commencement of employment, approved under Nasdaq Listing Rule 5635(c)(4).
Source:Jun 30, 2026, 12:00 UTC
SCYNEXIS initiated a Phase 1 study of SCY-770, a novel AMPK activator for ADPKD.
Source: